FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based ChemotherapyGwynn Ison, Richard Pazdur, Vadryn Pierre et al.|Clinical Cancer Research|2018Cited by 133
Outcomes of Older Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled AnalysisLynn Howie, Julia A. Beaver, Harpreet Singh et al.|Journal of Clinical Oncology|2019Cited by 91
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast CancerLynn Howie, Julia A. Beaver, Nancy S. Scher et al.|Clinical Cancer Research|2018Cited by 68